Sailing Pharmaceutical Technology Group

Sailing Pharmaceutical Technology Group is a China-based biotechnology company focused on the research, development, and manufacturing of innovative small molecule therapeutics. The company operates as an integrated platform providing contract research (CRO) and contract development and manufacturing (CDMO) services alongside its internal drug discovery programs. Sailing Pharmaceutical primarily targets metabolic diseases and oncology, with a notable focus on incretin-based therapies for diabetes and obesity. By leveraging its expertise in medicinal chemistry and process development, the company aims to accelerate the transition of novel drug candidates from preclinical stages to commercial production.